Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
| Autor: | Henry, Robert R, Lincoff, A Michael, Mudaliar, Sunder, Rabbia, Michael, Chognot, Cathy, Herz, Matthias |
|---|---|
| Zdroj: | In The Lancet 2009 374(9684):126-135 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|